Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Juan Carlos García Álvarez, Luz González Sánchez, Eloy García Resa, José María Bonete Llácer, Ana Román Rodríguez, Beatriz Pecino Esquerdo & Enrique Pérez Martínez. (2020) Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study. International Journal of Psychiatry in Clinical Practice 24:1, pages 10-17.
Read now
Read now
Rosaria Di Lorenzo, Paola Ferri, Michela Cameli, Sergio Rovesti & Chiara Piemonte. (2019) Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatric Disease and Treatment 15, pages 183-198.
Read now
Read now
Giovanni Amodeo, Chiara Candiracci, Ilaria Capecci, Sergio De Filippis, Sonia Giuliani, Giorgio Guerani, Carmine Tomasetti, Vincenzo Villari & Andrea Fagiolini. (2016) Starting aripiprazole long-acting-once-a-month early in treatment: why, how and for whom? Expert consensus and practical recommendations by a panel of Italian clinicians. Expert Opinion on Pharmacotherapy 17:16, pages 2143-2147.
Read now
Read now
Andrea Fagiolini, Emilia Alfonsi, Giovanni Amodeo, Mario Cenci, Michele Di Lella, Francesco Farinella, Fabrizio Ferraiuolo, David Fraguas, Natale Loparco, Luis Gutierrez-Rojas, Maria Laura Mignone, Giuseppe Pataracchia, Gianluca Pillai, Felicia Russo, Vanessa Sanchez-Gistau, Franco Spinogatti, Marco Toscano, Vincenzo Villari & Sergio De Filippis. (2016) Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. Expert Opinion on Drug Safety 15:4, pages 449-455.
Read now
Read now
Articles from other publishers (5)
Chencai Wang, Todd A. Tishler, Talia Oughourlian, Keith H. Nuechterlein, Camilo de la Fuente-Sandoval & Benjamin M. Ellingson. (2023) Prospective, randomized, multicenter clinical trial evaluating longitudinal changes in brain function and microstructure in first-episode schizophrenia patients treated with long-acting injectable paliperidone palmitate versus oral antipsychotics. Schizophrenia Research 255, pages 222-232.
Crossref
Crossref
Shuo Li, Ying He, Dianjun Sun, Zhaomeng Wang, Jiang Yu, Jianying Ye, Zhonggui He & Yongjun Wang. (2023) Long Acting Ionically Paired Pamoate-based Suspension of Lurasidone: An exploration of Size Effects on in vitro Dissolution and in vivo Pharmacokinetic Behaviors. AAPS PharmSciTech 24:4.
Crossref
Crossref
Minze Zhu, Andrew K. Whittaker, Felicity Y. Han & Maree T. Smith. (2022) Journey to the Market: The Evolution of Biodegradable Drug Delivery Systems. Applied Sciences 12:2, pages 935.
Crossref
Crossref
Nora Palomar-Ciria, Marta Migoya-Borja, Fanny Cegla-Schvartzman, Santiago Ovejero, Raquel Alvarez-Garcia, Hugo J. Bello & Enrique Baca-García. (2021) Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. International Clinical Psychopharmacology 36:2, pages 97-100.
Crossref
Crossref
Thomas BeresfordJennifer BuchananElizabeth Brie ThummChad EmrickDavid WeitzenkampPatrick J. Ronan. (2017) Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. Journal of Clinical Psychopharmacology 37:6, pages 657-663.
Crossref
Crossref